Gilead Sciences Inc. (GILD)
$125.45
$-1.78
(-1.40%)
As on 17-Jun-2026 16:00EDT
Market cap
$155,929 Mln
Revenue (TTM)
$29,734 Mln
P/E Ratio
17.1
P/B Ratio
6.6
Div. Yield
2.5 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.4 %
-
ROCE
18.2 %
-
Industry P/E
33.27
-
EV/EBITDA
11.8
-
Debt to Equity
0.9
-
Book Value
$--
-
EPS
$7.3
-
Face value
--
-
Shares outstanding
1,241,569,874
10 Years Aggregate
CFO
$115,888.00 Mln
EBITDA
$121,317.00 Mln
Net Profit
$75,750.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 2.2 | -3.2 | -13.6 | 13.2 | 16.7 | 13.3 | 4.2 |
|
BSE Sensex*
| -8.7 | 2.7 | 1.6 | -5.3 | 6.8 | 8.1 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 32.9 | 13.9 | -5.6 | 18.2 | 30.0 | -6.7 | 7.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
125.5 | 155,928.8 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.1 | 6.6 |
| 341.7 | 191,704.4 | 37,238.0 | 7,800.0 | 31.7 | 82.9 | 24.7 | 20.9 | |
| 198.7 | 29,534.8 | 9,857.4 | 1,372.4 | 18.4 | 7.4 | 21.5 | 1.6 | |
| 55.3 | 116,663.5 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.8 | |
| 226.3 | 52,427.0 | 250,549.0 | 1,559.0 | 0.9 | -- | 34.1 | 16.1 | |
| 779.8 | 94,623.4 | 403,430.0 | 4,762.0 | 1.6 | -246.4 | 20.5 | 5.0 | |
| 115.4 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 150.9 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 25.9 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 77.3 | 33,358.0 | 9,509.0 | 2,643.0 | 37.3 | 61.2 | 13 | 10.3 |
Shareholding Pattern
View DetailsAbout Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey,... Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Read more
-
Chairman & CEO
Mr. Daniel P. O'Day
-
Chairman & CEO
Mr. Daniel P. O'Day
-
Headquarters
Foster City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gilead Sciences (GILD)
What is the current share price of Gilead Sciences Inc (GILD) Today?
The share price of Gilead Sciences Inc (GILD) is $125.45 (NASDAQ) as of 17-Jun-2026 16:00 EDT. Gilead Sciences Inc (GILD) has given a return of 16.74% in the last 3 years.
What is the current PB & PE ratio of Gilead Sciences Inc (GILD)?
The P/E ratio of Gilead Sciences Inc (GILD) is 17.09 times as on 12-Jun-2026, a 49 discount to its peers’ median range of 33.27 times.
The P/B ratio of Gilead Sciences Inc (GILD) is 6.63 times as on 12-Jun-2026, a 15 premium to its peers’ median range of 5.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.07
|
6.77
|
|
2024
|
242.28
|
6.02
|
|
2023
|
17.96
|
4.46
|
|
2022
|
23.63
|
5.11
|
|
2021
|
14.72
|
4.35
|
What is the 52 Week High and Low of Gilead Sciences Inc (GILD)?
The 52-week high and low of Gilead Sciences Inc (GILD) are Rs 157.29 and Rs 104.46 as of 18-Jun-2026.
What is the market cap of Gilead Sciences Inc (GILD)?
Gilead Sciences Inc (GILD) has a market capitalisation of $ 155,929 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Gilead Sciences Inc (GILD)?
Before investing in Gilead Sciences Inc (GILD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.